Genetic Analysis to Evaluate the Racial Difference in the Outcome of Patients With Colon Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Colorectal Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/8/2015 |
| Start Date: | November 2011 |
| Contact: | Rangwasmy Govindarajan, MD |
| Email: | GovindarajanRang@uams.edu |
| Phone: | 501-686-8511 |
This is a retrospective genetic analysis of stored tumor tissue samples to evaluate the
distribution of Recurrence Score® and gene groups of stage II colon cancer in African
American (AA) and Caucasian individuals. Other covariant factors in the medical chart will
be analyzed as well. Three institutions will contribute patients to this study with a total
patient number goal of approximately 200 with approximately 100 being AA and approximately
100 being Caucasian. As enrollment in this study proceeds a Caucasian subject will be
matched for every African American enrolled.
distribution of Recurrence Score® and gene groups of stage II colon cancer in African
American (AA) and Caucasian individuals. Other covariant factors in the medical chart will
be analyzed as well. Three institutions will contribute patients to this study with a total
patient number goal of approximately 200 with approximately 100 being AA and approximately
100 being Caucasian. As enrollment in this study proceeds a Caucasian subject will be
matched for every African American enrolled.
Inclusion Criteria:
- Subjects must be 18 years of age or older.
- Subjects must be AA or Caucasian.
- Subjects with pathologic stage II colon cancer; Irrespective of number of nodes
examined.
Exclusion Criteria:
- Patients of races other than AA or Caucasian.
- No tumor block available from initial diagnosis.
- No tumor or very little tumor (<5% tumor present) in block as assessed by examination
of the H&E slide by the Genomic Health, Inc (GHI) - designated pathologist.
- Tumor types other than adenocarcinoma NOS (not otherwise specified) and mucinous
carcinoma as assessed by examination of the H&E slide by the GHI-designated
pathologist.
- Insufficient RNA (<5 ng/μL or 300 ng) for RT-PCR (radiation therapy - pathologic
complete response) analysis.
- Failure of assay to meet pre-specified quality control (QC) specifications.
We found this trial at
1
site
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
